Abacus规划集团股份公司购买了更多的Edwards Lifesciences股份,与其他投资者一道购买,尽管评级是“坚持”的。 Abacus Planning Group Inc. buys more Edwards Lifesciences shares, joining other investors despite a "Hold" rating.

Abacus规划集团公司扩大了其在Edwards Lifesciences公司的股票地位,收购了更多的股份,其他一些机构投资者也是如此。 Abacus Planning Group Inc. expanded its stock position in Edwards Lifesciences by acquiring additional shares, as did several other institutional investors. 该公司的股票被分析师评为“持有”,目标价格为79.95美元。 The company's stock is rated "Hold" by analysts with a target price of $79.95. 最近,内部人士出售了价值2 002 829美元的股票。 Recently, insiders have sold shares valued at $2,002,829. Edwards Lifesciences的市场上限为44.07亿美元,最近超过了对收入的预期。 Edwards Lifesciences has a market cap of $44.07 billion and recently surpassed earnings expectations.